Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Geron Corporation patents


Recent patent applications related to Geron Corporation. Geron Corporation is listed as an Agent/Assignee. Note: Geron Corporation may have other listings under different names/spellings. We're not affiliated with Geron Corporation, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Geron Corporation-related inventors


Aerobic exercise assistance apparatus

An aerobic exercise assistance apparatus 1 includes an input/output unit 131 that, under control by a control unit, gives a user a question and accepts an input of an answer from the user to the question while the user performs the aerobic exercise. The control unit controls the load application driving unit 110, 120 to change the load applied by the load application driving unit 110, 120, based on a correct answer ratio of the user for the question and timing of the answer to the question by the user.. ... Geron Corporation

2'-arabino-fluorooligonucleotide n3'˜p5' phosphoramidates: their synthesis and use

Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2′-arabino-fluoronucleoside and an internucleoside 3′-nh—p(—o)(or)—o-5′ linkage, where r is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2′-arabino-fluorooligonucleotides have a high rna binding affinity to complementary nucleic acids and are base and acid stable.. ... Geron Corporation

Rna amidates and thioamidates for rnai

The present disclosure relates to rna amidates and thioamidates useful for rna interference applications. The rna amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-n3′→p5′ phosphoramidate (np) and ribo-n3′→p5′ thiophosphoramidate (nps) linkages, and optionally further containing at least one covalently conjugated lipid moiety. ... Geron Corporation

Oligonucleotide compositions and methods of making the same

. . The present disclosure provides a solid phase method of making oligonucleotides via sequential coupling cycles including at least one coupling of a dinucleotide dimer subunit to a free 3′-terminal group of a growing chain. The oligonucleotides include at least two nucleoside subunits joined by a n3′→p5′ phosphoramidate linkage. ... Geron Corporation

Oligonucleotide compositions and methods of making the same

The present disclosure provides a solid phase method of making oligonucleotides via sequential coupling cycles including at least one coupling of a dinucleotide dimer subunit to a free 3′-terminal group of a growing chain. The oligonucleotides include at least two nucleoside subunits joined by a n3′→p5′ phosphoramidate linkage. ... Geron Corporation

Phosphorodiamidate backbone linkage for oligonucleotides

This invention relates to antisense oligonucleotides comprising at least one n3′→p5′ phosphorodiamidate linkage (npn) in the backbone as well as methods for using the same. The antisense oligonucleotides can effectively prevent or decrease protein expression.. ... Geron Corporation

Therapeutic agent for tauopathy and method for screening thereof

The present invention provides a tau protein aggregation inhibitor. In addition, a therapeutic agent or a preventive agent for tauopathy, including a tau protein aggregation inhibitor, and a method for screening for a tau protein aggregation inhibitor, are also provided. ... Geron Corporation

Biomarker for diagnosis of aging or amyotrophia

Provided is a novel biomarker for the diagnosis of aging or amyotrophy. Provided are a method for determining the state of aging or amyotrophy, a method for determining the efficacy of therapeutic or preventive effects on aging or amyotrophy, and a method of screening for a therapeutic or preventive agent for aging or amyotrophy. ... Geron Corporation

Guanine analogs as telomerase substrates and telomere length affectors

This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. ... Geron Corporation

Surrogate biomarker for evaluating intracerebral amyloid ß peptide accumulation and method for analysis thereof

Provided are a biomarker for evaluating a cerebral aβ accumulation state using an amyloid precursor protein (app)-derived peptide in a living body-derived sample as an index, and a method for analysis thereof. A living body-derived sample derived from a test subject is measured, and at least one ratio selected from the group consisting of app669-711/app672-713 (aβ1-42); app672-709 (aβ1-38)/app672-713 (aβ1-42); app674-711 (aβ3-40)/app672-713 (aβ1-42); app672-710 (aβ1-39)/app672-713 (aβ1-42); app672-711 (aβ1-40)/app672-713 (aβ1-42); and app672-711 (oxaβ1-40)/app672-713 (aβ1-42) is calculated, and when each of the ratios of the test subject is higher than each of standard levels which are ratios of a person having normal cognitive function nc− who is negative for cerebral aβ accumulation, an accumulation amount of cerebral aβ of the test subject is determined as larger than an accumulation amount of cerebral aβ of the person having normal cognitive function nc−.. ... Geron Corporation

Modified oligonucleotides for telomerase inhibition

Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the rna component of human telomerase. ... Geron Corporation

Pharmaceutical composition capable of accelerated penetration into affected area

Provided is a pharmaceutical composition excellent in capability of an accelerated penetration into an affected area. The pharmaceutical composition capable of accelerated penetration into the affected area is formed by dispersing nano-bubbles, which are negatively charged and are given high internal pressures due to their surface tension, in the pharmaceutical composition in a form of a liquid or a gel including a predetermined drug.. ... Geron Corporation

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have essential thrombocythemia (et). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having et.. ... Geron Corporation








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Geron Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Geron Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###